Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rob Boer

Showing results (21-30 of 36) with videos related to

Pageof 4
Sort By:
Journal of the National Cancer Institute|July 4, 2002
Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trendsRuth Etzioni, David F Penson, Julie M Legler, et al.
Cancer Causes & Control : CCC|October 29, 2010
Increased risk of adenomas in individuals with a family history of colorectal cancer: results of a meta-analysisJanneke A Wilschut, J Dik F Habbema, Scott D Ramsey, et al.
Journal of the National Cancer Institute|February 7, 2002
Cost-effectiveness of cervical cancer screening: comparison of screening policiesM Elske van den Akker-van Marle, Marjolein van Ballegooijen, Gerrit J van Oortmarssen, et al.
International Journal of Cancer|May 18, 2004
Mammography benefit in the Canadian National Breast Screening Study-2: a model evaluationAdriana J Rijnsburger, Gerrit J van Oortmarssen, Rob Boer, et al.
Gastrointestinal Endoscopy|May 27, 2009
Individualizing colonoscopy screening by sex and raceIris Lansdorp-Vogelaar, Marjolein van Ballegooijen, Ann G Zauber, et al.
International Journal of Cancer|July 9, 2004
National Polyp Study data: evidence for regression of adenomasFranka Loeve, Rob Boer, Ann G Zauber, et al.
International Journal of Cancer|November 16, 2005
Seventy-five years is an appropriate upper age limit for population-based mammography screeningJacques Fracheboud, Johanna Helëne Groenewoud, Rob Boer, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 5, 2008
Cost-effectiveness of primary versus secondary prophylaxis with pegfilgrastim in women with early-stage breast cancer receiving chemotherapyScott D Ramsey, Zhimei Liu, Rob Boer, et al.
Journal of the National Cancer Institute|February 10, 2010
Prostate-specific antigen screening in the United States vs in the European Randomized Study of Screening for Prostate Cancer-RotterdamElisabeth M Wever, Gerrit Draisma, Eveline A M Heijnsdijk, et al.
International Journal of Cancer|June 15, 2007
Human papillomavirus triage of women with persistent borderline or mildly dyskaryotic smears: Comparison of costs and side effects of three alternative strategiesMatejka Rebolj, Aagje G Bais, Marjolein van Ballegooijen, et al.
Pageof 4

Showing results (21-30 of 36) with videos related to

Sort By:
Pageof 4
Journal of the National Cancer Institute|July 4, 2002
Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trendsRuth Etzioni, David F Penson, Julie M Legler, et al.
Cancer Causes & Control : CCC|October 29, 2010
Increased risk of adenomas in individuals with a family history of colorectal cancer: results of a meta-analysisJanneke A Wilschut, J Dik F Habbema, Scott D Ramsey, et al.
Journal of the National Cancer Institute|February 7, 2002
Cost-effectiveness of cervical cancer screening: comparison of screening policiesM Elske van den Akker-van Marle, Marjolein van Ballegooijen, Gerrit J van Oortmarssen, et al.
International Journal of Cancer|May 18, 2004
Mammography benefit in the Canadian National Breast Screening Study-2: a model evaluationAdriana J Rijnsburger, Gerrit J van Oortmarssen, Rob Boer, et al.
Gastrointestinal Endoscopy|May 27, 2009
Individualizing colonoscopy screening by sex and raceIris Lansdorp-Vogelaar, Marjolein van Ballegooijen, Ann G Zauber, et al.
International Journal of Cancer|July 9, 2004
National Polyp Study data: evidence for regression of adenomasFranka Loeve, Rob Boer, Ann G Zauber, et al.
International Journal of Cancer|November 16, 2005
Seventy-five years is an appropriate upper age limit for population-based mammography screeningJacques Fracheboud, Johanna Helëne Groenewoud, Rob Boer, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 5, 2008
Cost-effectiveness of primary versus secondary prophylaxis with pegfilgrastim in women with early-stage breast cancer receiving chemotherapyScott D Ramsey, Zhimei Liu, Rob Boer, et al.
Journal of the National Cancer Institute|February 10, 2010
Prostate-specific antigen screening in the United States vs in the European Randomized Study of Screening for Prostate Cancer-RotterdamElisabeth M Wever, Gerrit Draisma, Eveline A M Heijnsdijk, et al.
International Journal of Cancer|June 15, 2007
Human papillomavirus triage of women with persistent borderline or mildly dyskaryotic smears: Comparison of costs and side effects of three alternative strategiesMatejka Rebolj, Aagje G Bais, Marjolein van Ballegooijen, et al.
Pageof 4